# EDGAR Filing Document

**Accession Number:** 0001124524
**File Stem:** 0000000000-25-008080
**Filing Date:** 2025-7
**Character Count:** 4089
**Document Hash:** 01cb271d9259ecb1f7bbf17a5a5d9e19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008080.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0000000000-25-008080

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250731

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cryoport, Inc.
- **CENTRAL INDEX KEY:** 0001124524
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880313393
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-34632

**BUSINESS ADDRESS:**
- **STREET 1:** 112 WESTWOOD PLACE, SUITE 350
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027
- **BUSINESS PHONE:** (949) 232-1900

**MAIL ADDRESS:**
- **STREET 1:** 112 WESTWOOD PLACE, SUITE 350
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CRYOPORT SYSTEMS LLC
- **DATE OF NAME CHANGE:** 20010614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CRYOPORT SYSTEMS INC
- **DATE OF NAME CHANGE:** 20000923
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001558370-25-002509

## Text-Extract

```

                                                              July 31, 2025

Robert S. Stefanovich
Chief Financial Officer
Cryoport, Inc.
112 Westwood Place, Suite 350
Brentwood, TN 37027

       Re: Cryoport, Inc.
           Form 10-K fo the fiscal year ended December 31, 2024
           File No. 001-34632
Dear Robert S. Stefanovich:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K fo the fiscal year ended December 31, 2024
ITEM 7. Management's Discussion and Analysis of Financial Condition and Results
of
Operations
Results of Operations
Revenue by type, page 42

1.     We note within your earnings release on Form 8-K as well as the earnings
call
       presentation that you quantify the amount of revenue earned related to
Commercial
       Cell & Gene Therapy. In fact, it is the first bullet in your earnings
release for the first
       quarter of 2025 and you have emphasized those results in that period's
earnings call.
       Therefore, please tell us and quantify in future filings the Commercial
Cell & Gene
       Therapy revenue that is included in each of your three operating
segments. Refer
       to Item 303(a) of Regulation S-K. Further, tell us and disclose the
significant
       components of each of the three operating segments and provide an
analysis of the
       changes in each of those components pursuant to Item 303(b)(2)(i) and
(ii) of
       Regulation S-K, as it is not clear from the description of your products
and services on
       pages 5-7 into what operating segments these products and services are
included. For
       example, it should be clear to a reader what is included within
BioLogistics Solutions,
 July 31, 2025
Page 2

       which accounts for 60% of your consolidated revenue for the year ended
December
       31, 2024.
        In closing, we remind you that the company and its management are
responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.

       Please contact Vanessa Robertson at 202-551-3649 or Jenn Do at
202-551-3743 with
any questions.

                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._